NL8502063A - Syntetische genen voor runder-parainfluenza-virus, vectoren of plasmiden voor die genen, gastheercellen die ze bevatten, door die gastheercellen gevormd eiwit en werkwijze voor het bereiden van dat alles. - Google Patents
Syntetische genen voor runder-parainfluenza-virus, vectoren of plasmiden voor die genen, gastheercellen die ze bevatten, door die gastheercellen gevormd eiwit en werkwijze voor het bereiden van dat alles. Download PDFInfo
- Publication number
- NL8502063A NL8502063A NL8502063A NL8502063A NL8502063A NL 8502063 A NL8502063 A NL 8502063A NL 8502063 A NL8502063 A NL 8502063A NL 8502063 A NL8502063 A NL 8502063A NL 8502063 A NL8502063 A NL 8502063A
- Authority
- NL
- Netherlands
- Prior art keywords
- protein
- virus
- gene
- mrna
- dna
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 173
- 102000004169 proteins and genes Human genes 0.000 title claims description 106
- 238000000034 method Methods 0.000 title claims description 55
- 108700005078 Synthetic Genes Proteins 0.000 title claims description 38
- 239000013598 vector Substances 0.000 title claims description 30
- 241000712005 Bovine respirovirus 3 Species 0.000 title claims description 24
- 239000013612 plasmid Substances 0.000 title claims description 17
- 241000700605 Viruses Species 0.000 claims description 146
- 108020004999 messenger RNA Proteins 0.000 claims description 111
- 239000002299 complementary DNA Substances 0.000 claims description 104
- 108020004414 DNA Proteins 0.000 claims description 52
- 101710154606 Hemagglutinin Proteins 0.000 claims description 29
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 29
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 29
- 101710176177 Protein A56 Proteins 0.000 claims description 29
- 239000000185 hemagglutinin Substances 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 108020004705 Codon Proteins 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 108091027963 non-coding RNA Proteins 0.000 claims description 2
- 102000042567 non-coding RNA Human genes 0.000 claims description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 3
- 102100034343 Integrase Human genes 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 description 94
- 238000010804 cDNA synthesis Methods 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 52
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 238000009396 hybridization Methods 0.000 description 23
- 230000014616 translation Effects 0.000 description 21
- 238000013519 translation Methods 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000020 Nitrocellulose Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229920001220 nitrocellulos Polymers 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 238000000376 autoradiography Methods 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 229940113082 thymine Drugs 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001293418 Mannheimia haemolytica Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LWXNQQIVUUSCSL-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol trihydrochloride Chemical compound Cl.Cl.Cl.OCC(N)(CO)CO LWXNQQIVUUSCSL-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- UZHDGDDPOPDJGM-UHFFFAOYSA-N Stigmatellin A Natural products COC1=CC(OC)=C2C(=O)C(C)=C(CCC(C)C(OC)C(C)C(C=CC=CC(C)=CC)OC)OC2=C1O UZHDGDDPOPDJGM-UHFFFAOYSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000004395 glucoside group Chemical group 0.000 description 1
- 125000003563 glycoside group Chemical group 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 125000005287 vanadyl group Chemical group 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/632,106 US4743553A (en) | 1984-07-18 | 1984-07-18 | Synthetic genes for bovine parainfluenza virus |
| US63210684 | 1984-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8502063A true NL8502063A (nl) | 1986-02-17 |
Family
ID=24534103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8502063A NL8502063A (nl) | 1984-07-18 | 1985-07-17 | Syntetische genen voor runder-parainfluenza-virus, vectoren of plasmiden voor die genen, gastheercellen die ze bevatten, door die gastheercellen gevormd eiwit en werkwijze voor het bereiden van dat alles. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4743553A (de) |
| AU (1) | AU588238B2 (de) |
| BE (1) | BE902921A (de) |
| DE (1) | DE3524736A1 (de) |
| DK (1) | DK326185A (de) |
| ES (1) | ES8608581A1 (de) |
| FR (1) | FR2567905B1 (de) |
| GB (1) | GB2161814A (de) |
| IT (1) | IT1187689B (de) |
| NL (1) | NL8502063A (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003206A1 (en) * | 1985-11-25 | 1987-06-04 | Quash Gerard A | Modified viral glycoproteins, diagnostic and therapeutic uses therefore |
| AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
| US5149650A (en) * | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| AU611784B2 (en) * | 1988-04-22 | 1991-06-20 | Pharmacia & Upjohn Company | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 |
| NZ230425A (en) * | 1988-09-02 | 1992-07-28 | Molecular Eng Ass | Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector |
| JPH0757200B2 (ja) * | 1989-06-19 | 1995-06-21 | 藤倉化成株式会社 | ヒトパラインフルエンザ２型ウイルス同定用検査薬に用いるｄｎａ断片 |
| US5401626A (en) * | 1989-06-18 | 1995-03-28 | Fujikura Kasei Co., Ltd. | cDNA fragment of the gene for the hemagglutinin neuraminidase of human parainfluenza type 2 virus and materials containing the cDNA fragment |
| JP2649285B2 (ja) * | 1990-11-29 | 1997-09-03 | 藤倉化成株式会社 | ヒトパラインフルエンザ４ａ型ウイルスフュージョンプロテイン遺伝子及び該遺伝子を含む物質 |
| AU706454B2 (en) * | 1994-11-18 | 1999-06-17 | Bayer Aktiengesellschaft | Expression of the bovine parainfluenza virus type 3 hemagglutinin/neuraminidase (HN) glycoprotein in two heterologous systems |
| US5869036A (en) * | 1995-12-08 | 1999-02-09 | St. Louis University | Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine |
| US20040176855A1 (en) * | 2003-03-07 | 2004-09-09 | Acell, Inc. | Decellularized liver for repair of tissue and treatment of organ deficiency |
| US20040175366A1 (en) * | 2003-03-07 | 2004-09-09 | Acell, Inc. | Scaffold for cell growth and differentiation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3501770A (en) * | 1967-04-13 | 1970-03-17 | Lilly Co Eli | Shipping fever vaccine |
| DE2323847C3 (de) * | 1973-05-11 | 1979-11-22 | Bayer Ag, 5090 Leverkusen | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion |
| GB1488800A (en) * | 1973-11-29 | 1977-10-12 | Wellcome Found | Influenza vaccines |
| US4331589A (en) * | 1978-11-22 | 1982-05-25 | Abbott Laboratories | Deoxyribonucleic acid synthesis using binding protein extracted from chick embryo fibroblasts |
| FR2480779B2 (fr) * | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| US4357421A (en) * | 1979-04-02 | 1982-11-02 | G. D. Searle & Co. | Synthetic gene coding for influenza hemagglutinin |
| US4415491A (en) * | 1980-01-14 | 1983-11-15 | The Regents Of The University Of California | Synthetic vaccine peptide epitomes of hepatitis B surface antigen |
| US4335106A (en) * | 1980-03-31 | 1982-06-15 | Norden Laboratories Inc. | Processes for the growth of a modified Pasteurella multocida bacteria and preparation of a vaccine therefrom |
| US4293545A (en) * | 1980-03-31 | 1981-10-06 | Norden Laboratories, Inc. | Modified Pasteurella multocida bacteria vaccines |
| US4328210A (en) * | 1980-03-31 | 1982-05-04 | Norden Laboratories, Inc. | Modified Pasteurella bacteria and vaccines prepared therefrom |
| US4388299A (en) * | 1980-03-31 | 1983-06-14 | Norden Laboratories, Inc. | Modified pasteurella bacteria and vaccines prepared therefrom |
| US4719177A (en) * | 1981-04-20 | 1988-01-12 | Massachusetts Institute Of Technology | Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor |
| US4393201A (en) * | 1981-11-04 | 1983-07-12 | The Wistar Institute | DNA Which codes for glycoprotein of era-strain rabies virus |
| FR2524487B1 (fr) * | 1982-04-05 | 1985-11-22 | Pasteur Institut | Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants |
| CA1198882A (en) * | 1982-04-08 | 1986-01-07 | Marley Tile A.G. | Roof tiles |
| DE3382459D1 (de) * | 1982-04-14 | 1991-12-19 | James L Bittle | Kuenstliches pikornavirusantigen. |
-
1984
- 1984-07-18 US US06/632,106 patent/US4743553A/en not_active Expired - Fee Related
-
1985
- 1985-06-28 AU AU44417/85A patent/AU588238B2/en not_active Ceased
- 1985-07-11 DE DE19853524736 patent/DE3524736A1/de not_active Withdrawn
- 1985-07-17 FR FR8510975A patent/FR2567905B1/fr not_active Expired
- 1985-07-17 NL NL8502063A patent/NL8502063A/nl not_active Application Discontinuation
- 1985-07-17 BE BE0/215370A patent/BE902921A/fr not_active IP Right Cessation
- 1985-07-17 ES ES545299A patent/ES8608581A1/es not_active Expired
- 1985-07-17 DK DK326185A patent/DK326185A/da not_active Application Discontinuation
- 1985-07-17 IT IT21609/85A patent/IT1187689B/it active
- 1985-07-17 GB GB08517994A patent/GB2161814A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BE902921A (fr) | 1985-11-18 |
| IT1187689B (it) | 1987-12-23 |
| ES8608581A1 (es) | 1986-07-16 |
| FR2567905A1 (fr) | 1986-01-24 |
| ES545299A0 (es) | 1986-07-16 |
| GB8517994D0 (en) | 1985-08-21 |
| AU588238B2 (en) | 1989-09-14 |
| DK326185D0 (da) | 1985-07-17 |
| DE3524736A1 (de) | 1986-01-30 |
| IT8521609A0 (it) | 1985-07-17 |
| AU4441785A (en) | 1986-01-23 |
| US4743553A (en) | 1988-05-10 |
| GB2161814A (en) | 1986-01-22 |
| FR2567905B1 (fr) | 1988-03-11 |
| DK326185A (da) | 1986-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5091309A (en) | Sindbis virus vectors | |
| KR0179994B1 (ko) | 칠면조의 재조합 포진바이러스 및 이로부터 유도된 생존상태의 벡터 백신 | |
| EP0218625B1 (de) | Spike-protein des virus der infektiösen bronchitis | |
| US5021347A (en) | Recombinant vaccinia virus expressing E-protein of Japanese encephalitis virus | |
| JPS61289888A (ja) | ワクシニアｄｎａ | |
| JP2528815B2 (ja) | 多効果免疫性蛋白質 | |
| WO1989012695A1 (en) | Dna amplification and subtraction techniques | |
| NL8502063A (nl) | Syntetische genen voor runder-parainfluenza-virus, vectoren of plasmiden voor die genen, gastheercellen die ze bevatten, door die gastheercellen gevormd eiwit en werkwijze voor het bereiden van dat alles. | |
| GB2218421A (en) | A recombinant baculovirus, envelope protein of Japanese encephalitis virus using said virus and process for producing the protein. | |
| US4847081A (en) | Synthetic bovine parainfluenza viral proteins | |
| Ling et al. | Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus | |
| JPS63188390A (ja) | 抗原として活性なタンパク質及びペプチド、並びに伝染性胃腸炎ウイルス・ワクチン | |
| EP0117063A1 (de) | Methoden und Materialien zur Entwicklung von Parvovirus-Vakzin | |
| GB2084583A (en) | Synthetic dna and process therefor | |
| EP0411684A2 (de) | Antigenische Peptide/Proteine und Vakzine gegen infectiöse Katzenbauchfellentzündung | |
| EP0257994B1 (de) | Für das Rinderpestvirus-Antigen kodierende DNS, ihre Herstellung und Verwendung | |
| CN117050158B (zh) | 一种红嘴鸥IFN-γ基因及其编码的重组蛋白的应用 | |
| JP3140019B2 (ja) | ヒトサイトメガロウィルスの構造燐タンパク質（ｐｐ２８）、その製造および使用 | |
| Weber et al. | Nucleic acids of RNA tumor viruses: identification and ultrastructure | |
| US6939957B2 (en) | Nucleotide sequences of the nucleocapsid (NP) gene of a Malaysian velogenic Newcastle disease virus strain AF2240 | |
| AU620628C (en) | DNA amplification and subtraction techniques | |
| KR0142210B1 (ko) | 돼지파보바이러스 vp2 단백질의 대량 생산방법 및 돼지파보바이러스 감염증용 백신용 백신의 제조방법 | |
| CN114908065A (zh) | 猪伪狂犬病病毒基因工程弱毒疫苗株及其建立方法和应用 | |
| Kemdirim | Molecular cloning of the polymerase genes of influenza B virus: complete nucleotide sequence of the virus genome RNA segment encoding the PBI protein | |
| KR19980047324A (ko) | 개 파보바이러스를 이용한 유전자 재조합 베큘로바이러스, 이를 이용한 vp2 재조합 단백질의 생산방법 및 이 재조합 단백질을 이용한 개파보바이러스 감염증 백신 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: GRACE & CO.-CONN. W.R. - |
|
| BV | The patent application has lapsed |